Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.

[Q]: Context: Can you name some fossils? How about dinosaur bones or dinosaur footprints? Animal skeletons, teeth, shells, coprolites (otherwise known as feces), or any other remains or traces from a living creature that becomes rock is a fossil. The same processes that formed these fossils also created some of our most important energy resources, fossil fuels. Coal, oil, and natural gas are fossil fuels. Fossil fuels come from living matter starting about 500 million years ago. Millions of years ago, plants used energy from the Sun to form sugars, carbohydrates, and other energy-rich carbon compounds. As plants and animals died, their remains settled on the ground on land and in swamps, lakes, and seas (Figure 1.1). Over time, layer upon layer of these remains accumulated. Eventually, the layers were buried so deeply that they were crushed by an enormous mass of earth. The weight of this earth pressing down on these plant and animal remains created intense heat and pressure. After millions of years of heat and pressure, the material in these layers turned into chemicals called hydrocarbons (Figure 1.2). Hydrocarbons are made of carbon and hydrogen atoms. This molecule with one carbon and four hydrogen atoms is methane. Hydrocarbons can be solid, liquid, or gaseous. The solid form is what we know as coal. The liquid form is petroleum, or crude oil. Natural gas is the gaseous form. The solar energy stored in fossil fuels is a rich source of energy. Although fossil fuels provide very high quality energy, they are non-renewable. Click image to the left or use the URL below. URL: 
 Question: hydrocarbons in solid form are called _________________.
[A]: coal


[Q]: Context: Coming off their bye week, the Jets stayed at home for a Week 10 duel with the Jacksonville Jaguars. New York would trail early in the first quarter with running back Maurice Jones-Drew's 33-yard touchdown run. The Jets would respond with kicker Jay Feely getting a 32-yard field goal, followed by rookie quarterback Mark Sanchez completing a 7-yard touchdown pass to wide receiver Jerricho Cotchery. In the second quarter, Jacksonville would take the lead as quarterback David Garrard got an 11-yard touchdown run and completed a 26-yard touchdown pass to wide receiver Mike Sims-Walker. New York would close out the half as Feely made a 37-yard field goal. After a scoreless third quarter, the Jets would regain the lead in the fourth quarter with a 40-yard field goal from Feely and a 1-yard touchdown run from running back Thomas Jones (with a failed 2-point conversion). However, the Jaguars got the last laugh as kicker Josh Scobee booted the game-winning 21-yard field goal. 
 Question: Which team scored less during the first quarter?
[A]: jaguars


[Q]: Context: Idarucizumab, a monoclonal antibody fragment that binds dabigatran with high affinity, is in development as a specific antidote for dabigatran. In this first-in-human, single-rising-dose study, we investigated the pharmacokinetics, safety and tolerability of idarucizumab. Healthy male volunteers aged 18-45 years received between 20 mg and 8 g idarucizumab as a 1-hour intravenous infusion in 10 sequential dose groups, or 1, 2 or 4 g idarucizumab as a 5-minute infusion. Subjects within each dose group were randomised 3:1 to idarucizumab or placebo. A total of 110 randomised subjects received study drug (27 placebo, 83 idarucizumab). Peak and total exposure to idarucizumab increased proportionally with dose. Maximum plasma concentrations were achieved near the end of infusion, followed by a rapid decline, with an initial idarucizumab half-life of ~45 minutes. For the 5-minute infusions, this resulted in a reduction of plasma concentrations to less than 5% of peak within 4 hours. Idarucizumab (in the absence of dabigatran) had no effect on coagulation parameters or endogenous thrombin potential. Overall adverse event (AE) frequency was similar for idarucizumab and placebo, and no relationship with idarucizumab dose was observed. Drug-related AEs (primary endpoint) were rare (occurring in 2 placebo and 3 idarucizumab subjects) and were mostly of mild intensity; none of them resulted in study discontinuation. In conclusion, the pharmacokinetic profile of idarucizumab meets the requirement for rapid peak exposure and rapid elimination, with no effect on pharmacodynamic parameters. Idarucizumab was safe and well tolerated in healthy males. 
 Question: Which drug can be reversed with idarucizumab?
[A]:
dabigatran